Meagan B. Ryan

2.4k citations

17 papers · 1.1k indexed · 1 hit paper · h-index 11

Impact in

Oncology top 10%
- Peptidase Inhibition and Analysis
Molecular Biology top 10%
- Protein Kinase Regulation and GTPase Signaling
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors

Papers in

Pathology and Forensic Medicine 4
- Cancer Mechanisms and Therapy 4
Oncology 6
- Peptidase Inhibition and Analysis 2

Co-authors: Ryan B. Corcoran Channing J. Der Adrienne D. Cox Andrea Wang‐Gillam Chendi Li W. Marston Linehan Aaron N. Hata Jochen K. Lennerz
Journals: Cancer Discovery (3 papers)Molecular Cancer Research (2 papers)Molecular Cancer Therapeutics (2 papers)Nature Reviews Clinical Oncology (1 paper)Trends in cancer (1 paper)
Partner nations: United States Switzerland Israel

In The Last Decade

Meagan B. Ryan

16 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation 2021 · 302 citations

Peers

Countries citing papers authored by Meagan B. Ryan

Since Specialization

Citations

This map shows the geographic impact of Meagan B. Ryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meagan B. Ryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meagan B. Ryan more than expected).

Fields of papers citing papers by Meagan B. Ryan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meagan B. Ryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meagan B. Ryan. The network helps show where Meagan B. Ryan may publish in the future.

Co-authors

The 25 scholars most cited alongside Meagan B. Ryan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Meagan B. Ryan Line = papers co-authored together Meagan B. Ryan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers Cancer Discovery ·Meagan B. Ryan, Bradley Quade, Natasha Schenk, Joseph E. Nassar, Романова Наталья Ивановна, B. Paschen, Chang Xin-sheng, Lui Libing, Ayşegül Özen, Chaoyang Ye, Maria Stella Ritorto, Xin Huang, Arvin C. Dar, Yongxin Han, Klaus P. Hoeflich, Michael Hale, Margit Hagel	2024	16
2	Cell type–specific epigenetic priming of gene expression in nucleus accumbens by cocaine Science Advances ·Philipp Mews, Yentl Y. van der Zee, Alicja Kamińska, Molly Estill, 岡本誉充, Hope Kronman, Aarthi Ramakrishnan, Meagan B. Ryan, Alex Baird, Benjamin A. Garcia, Caleb J. Browne, Simone Sidoli, Li Shen, Eric J. Nestler	2024	6
3	Abstract A086: NST-628 is a novel molecular glue that inhibits signaling and pathway reactivation in oncogenic RAS-MAPK cancers Molecular Cancer Therapeutics ·Bradley Quade, Meagan B. Ryan, Chang Xin-sheng, Steven I. Cohen, Zhong Fang, Ayşegül Özen, Xin Huang, Arvin C. Dar, Yongxin Han, Klaus P. Hoeflich, Margit Hagel, Michael Hale	2023	1
4	KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy Cell Reports ·Meagan B. Ryan, Mohinur Abdurahmon qizi Boboqulova, Alexey V. Sorokin, Kally Inês Lins, 恒好石田, Edmond Wong, Preeti Kanikarla Marie, Fengqin Gao, Youyan Zhang, Lian Zhou, Scott Kopetz, Ryan B. Corcoran	2022	76
5	Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression Molecular Cell ·Ioannis Sanidas, Thamille Gama Souza Santos, Devardarssen Murdamoothoo, Gaylor Boulay, Robert Morris, М.К. Овезов, Marcello Stanzione, Soroush Hajizadeh, Jun Zhong, Meagan B. Ryan, Ryan B. Corcoran, Benjamin J. Drapkin, Miguel N. Rivera, Nicholas J. Dyson, Michael S. Lawrence	2022	16
6	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation Cancer Discovery ·Noritaka Tanaka, W. Marston Linehan, Chendi Li, Meagan B. Ryan, Junbing Zhang, Lesli A. Kiedrowski, Alexa Michel, Mohammed U. Syed, Kally Inês Lins, Mustafa Sakhi, Islam Baiev, Dejan Juric, Justin F. Gainor, Samuel J. Klempner, Jochen K. Lennerz, Giulia Siravegna, Liron Bar‐Peled, Aaron N. Hata, Rebecca S. Heist, Ryan B. Corcoran Hit paper breakdown →	2021	302
7	Abstract B50: ERK MAPK inhibition enhances the immunogenicity of KRAS-mutant colorectal cancer Molecular Cancer Research ·Meagan B. Ryan, Ferran Fece de la Cruz, Leanne G. Ahronian, Sarah Phat, David T. Myers, Heather A. Shahzade, Catriona B. Hong, Ryan B. Corcoran	2020	0
8	Abstract A129: Vertical inhibition overcomes adaptive resistance to KRASG12C inhibition Molecular Cancer Therapeutics ·Meagan B. Ryan, Ferran Fece de la Cruz, Sarah Phat, David T. Myers, Heather A. Shahzade, Catriona B. Hong, Ryan B. Corcoran	2019	1
9	Therapeutic strategies to target RAS-mutant cancers Nature Reviews Clinical Oncology ·Meagan B. Ryan, Ryan B. Corcoran	2018	250
10	ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma Molecular Cancer Research ·Meagan B. Ryan, Alexander J. Finn, Sajjad M. Yousafzai, Nancy E. Thomas, Channing J. Der, Adrienne D. Cox	2016	28
11	USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds Proceedings of the National Academy of Sciences ·Babita Madan, Matthew P. Walker, Robert Young, Laura Quick, Kelly Orgel, Meagan B. Ryan, Zhang Jin-xing, René Mahrer, Marc Ferrer, Shane Marine, Brian S. Roberts, William T. Arthur, Jason D. Berndt, André M. Oliveira, Randall T. Moon, David M. Virshup, Margaret M. Chou, Michael B. Major	2016	79
12	Targeting RAS -mutant Cancers: Is ERK the Key? Trends in cancer ·Meagan B. Ryan, Channing J. Der, Andrea Wang‐Gillam, Adrienne D. Cox	2015	100
13	GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB Cancer Discovery ·David Houglum, Willie Wilson, Meagan B. Ryan, Jen Jen Yeh, Albert S. Baldwin	2013	73
14	Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration Journal of Biological Chemistry ·Kendra A. Williams, Mu Zhang, Shengyan Xiang, Hu Chen, 明美中澤, Shengping Zhang, Meagan B. Ryan, Adrienne D. Cox, Channing J. Der, Bin Fang, John M. Koomen, Eric B. Haura, Gerold Bepler, Santo V. Nicosia, Patrick Matthias, Chuangui Wang, Wenlong Bai, Xiaohong Zhang	2013	90
15	CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells Cancer Chemotherapy and Pharmacology ·Zhenfeng Duan, 岩田岳, Meagan B. Ryan, Francis J. Hornicek, Henry J. Mankin, Michael V. Seiden	2008	65
16	The use of stem cell assays to monitor the proliferative potential of bone marrow cells. PubMed ·P. J. Quesenberry, Lee Levitt, Francis C. Monette, Louvel Brice, Kenneth S. Zuckerman, Ruth Sullivan, Meagan B. Ryan	1979	2
17	A Dichotomy between the Release of Bone Marrow Granulocytes and Stem Cells Experimental Biology and Medicine ·Peter J. Quesenberry, Kenneth S. Zuckerman, Meagan B. Ryan, Frederick Stohlman	1977	3

About Meagan B. Ryan

Meagan B. Ryan is a scholar working on Pathology and Forensic Medicine, Oncology, Virology, Molecular Biology and Immunology and Allergy, having authored 17 papers that have together received 1.1k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (6 papers), Cancer Mechanisms and Therapy (4 papers), Protein Degradation and Inhibitors (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Protein Tyrosine Phosphatases (2 papers), Cancer therapeutics and mechanisms (2 papers), Peptidase Inhibition and Analysis (2 papers) and Ubiquitin and proteasome pathways (2 papers). The work is most often cited by research in Oncology (432 citations), Molecular Biology (816 citations), Cancer Research (177 citations), Cell Biology (98 citations) and Pathology and Forensic Medicine (101 citations). Meagan B. Ryan has collaborated with scholars based in United States, Switzerland and Israel. Frequent co-authors include Ryan B. Corcoran, Channing J. Der, Adrienne D. Cox, Andrea Wang‐Gillam, Chendi Li, W. Marston Linehan, Aaron N. Hata, Jochen K. Lennerz, Mohammed U. Syed and Samuel J. Klempner. Their work appears in journals such as Cancer Discovery, Molecular Cancer Research, Molecular Cancer Therapeutics, Nature Reviews Clinical Oncology and Trends in cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact